Login to Your Account



Agreement Targets Brazilian Market

Epirus and Orygen Partner in $275M Biosimilars Deal

By Catherine Shaffer
Staff Writer

Wednesday, October 23, 2013
Epirus Switzerland GmbH, of Zug, Switzerland, will earn up to $275 million in up-front, milestone and royalty payments under a new partnership with Orygen Biotecnologia Ltda, a joint venture of Brazilian pharmaceutical firms Eurofarma Laboratorios SA and Biolab Sanus Farmaceutica Ltda. The companies will work to register a biosimilar of Remicade (infliximab, Johnson & Johnson), BOW015, with Brazil’s National Agency of Sanitary Surveillance.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription